Funder
NIH
Ovarian Cancer Research Alliance
NCI
Subject
Obstetrics and Gynaecology,Oncology
Reference29 articles.
1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019
2. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy;Domchek;Gynecol. Oncol.,2016
3. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial;Pujade-Lauraine;Lancet Oncol,2017
4. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial;Ledermann;Lancet Oncol,2014
5. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer;Ledermann;N. Engl. J. Med.,2012
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献